Novo Nordisk has entered into a strategic collaboration and licensing agreement with The United Laboratories (TUL) to develop UBT251, a triple receptor agonist targeting GLP-1, GIP, and glucagon. The deal, valued at up to US$2 B, aligns with Novo Nordisk's strategy to enhance its cardiometabolic pipeline and provides TUL with significant funding to advance its other programmes. This collaboration follows recent high-profile deals in the sector, including AbbVie's partnership with Gubra and Roche's agreement with Zealand Pharma.